Rachel Narozniak, MA

Articles

PD-L1 Status Guides TIL activity in NeoTRIPaPDL1

September 19th 2020

Although atezolizumab did not improve pathological complete response when added to carboplatin and nab-paclitaxel, the immunotherapy increased the pCR by 10% or more in “immune-rich” groups with high-risk and locally advanced triple-negative breast cancer, and also turned PD-L1 negative tumors positive in most immunotherapy-treated patients.

Investigator Looks to Novel Therapy to Advance TP53-Mutant MDS Landscape

September 17th 2020

David P. Steensma, MD, discusses the importance of evaluating eprenetapopt in the pivotal phase 3 study, the agent’s potential role in the MDS landscape, and some of the questions that remain in this setting.

Ramucirumab Maintains Activity, Tolerability After Non-Sorafenib Frontline Therapy in HCC

September 15th 2020

The safety and efficacy of ramucirumab administered after a frontline, non–sorafenib-based systemic therapy in hepatocellular carcinoma was consistent with data from the sorafenib-receiving intention-to-treat population of the phase 3 REACH-2 study.

Relapsed/Refractory DLBCL Paradigm Gains Chemotherapy-Free Option

September 15th 2020

Kami J. Maddocks, MD, discusses the tolerability and promise of tafasitamab in combination with lenalidomide in relapsed or refractory DLBCL.

Daiichi Sankyo, Gustave Roussy Research Partnership Holds Promise for NSCLC, Breast Cancer Paradigms

September 8th 2020

A multi-year, multi-study research collaboration between Daiichi Sankyo and Gustave Roussy Cancer Center will support the clinical, translational, and preclinical evaluation of 2 of the company’s lead antibody-drug conjugates: DS-1062 in advanced non–small cell lung cancer, and patritumab deruxtecan in metastatic breast cancer.

Expanded Lung Cancer Screening Criteria Would Boost Survival Outcomes

September 5th 2020

Under a draft recommendation proposed by the US Preventive Services Task Force, individuals who are at a high risk for developing lung cancer because of their smoking history would begin annual screening with low-dose computed tomography at aged 50 years.

Studies Explore a New Role for CDK4/6 Inhibition in HR+/HER2+ Breast Cancer and TNBC

September 2nd 2020

Priyanka Sharma, MD, discusses how data from early clinical studies suggest a role for CDK4/6 inhibitor-based combinations in hormone receptor- positive, HER2-positive breast cancer and triple-negative breast cancer.

Liquid Biopsy Field Moves Forward But Faces Hurdles

September 2nd 2020

Technological advancements are rapidly expanding the potential uses for blood-based liquid biopsies, but broad clinical adoption in cancer care hinges on improving the knowledge base of practicing oncologists and gathering prospective data to validate assays.

First Targeted Regimen Arrives for BRAF V600E-Mutant mCRC

September 1st 2020

The approval of encorafenib in combination with cetuximab advances the metastatic colorectal cancer paradigm, introducing a biomarker-specific regimen for patients with pretreated BRAF V600E–mutant disease.

Companion Diagnostic, Targeted Therapy Approvals Rise in Tandem

August 23rd 2020

As precision medicine evolves in oncology, companion diagnostics are broadly and increasingly being adopted to guide treatment decisions, enabling clinicians to better and more precisely direct patients to therapies that best suit their unique genomic profiles.

Tazemetostat Expands Follicular Lymphoma Tool Kit

August 18th 2020

The approval of tazemetostat has expanded the portfolio of treatment options for relapsed/refractory follicular lymphoma, a disease for which new agents are needed because patients do not uniformly derive benefit from available therapies.

Biomarker-Driven Monotherapy Enters mCRPC Paradigm

August 15th 2020

The PARP inhibitor olaparib is now available for patients with metastatic castration-resistant prostate cancer whose tumors harbor mutations in homologous recombination repair genes.

Immuno-oncology Agents Face Off in NSCLC

August 10th 2020

Investigators will pit 2 PD-1/PD-L1–pathway agents against each other in a bid to determine which therapy can confer the greatest survival benefit in patients with PD-L1–high, advanced non–small cell lung cancer.

Immune Checkpoint Inhibitor Therapy Is Linked to COVID-19 Severity

August 10th 2020

Immunotherapy use is associated with a higher risk for hospitalization and severe coronavirus disease 2019 infection in patients with cancer and the novel respiratory virus.

Ripretinib Approval Advances Recurrent GIST Paradigm

August 3rd 2020

Ripretinib has become the first therapy specifically approved for the fourth-line treatment of gastrointestinal stromal tumors, a clinical setting with an unmet medical need because of the poor prognosis of patients with progressive disease.

New Focus Needed on Preventing Brain Metastases in Early Breast Cancer

August 1st 2020

Although strategies for treating brain metastases in patients with advanced breast cancer are showing signs of efficacy, new approaches are needed to prevent high-risk, HER2-positive early disease from spreading to the central nervous system.

Long-Term Consequences for Cancer Detection Loom Amid COVID-19

July 30th 2020

The coronavirus disease 2019 has disrupted the global delivery of coordinated cancer care, resulting in declines in routine screening and referrals that could lead to thousands of excess deaths due to delayed diagnoses, experts warn.

USPSTF Seeks To Expand Age, Pack-Year LDCT Screening Criteria

July 26th 2020

New Tools Support Translational Strides in NSCLC

July 23rd 2020

In non–small cell lung cancer, single cell analytics, genome editing, and next-generation animal models represent just some of the modern modalities advancing translational research.

Investigators Take Aim at GBM With a Biomarker-Driven Approach

July 21st 2020

Efforts are underway to expedite the identification of therapies that offer promise for patients with glioblastoma